Waters (WAT) Beat Q1 Revenue Estimates, Is It Still Below Fair Value?
Waters Q1 surprise puts fresh focus on the stock
Waters (WAT) drew fresh investor attention after Q1 revenue exceeded analyst expectations by 4.5% and management issued revenue guidance for the next quarter that came in above prior estimates.
The company also led the research tools and consumables sector in both revenue growth and estimate beats, and its CEO credited the combined company’s teams for delivering what he called excellent first quarter results.
See our latest analysis for Waters.
Waters shares trade at US$368.98. While the stock fell 2.44% on a 1-day share price return basis and is down 3.40% year to date, investors still saw a 28.33% total shareholder return over the past year, suggesting recent Q1 strength is being weighed against a mixed longer term record.
If this Q1 surprise has you rethinking where growth in lab and data infrastructure could emerge next, it may be worth scanning 54 AI infrastructure stocks
Waters now trades about 12% below the average analyst price target and at an estimated 22% discount to intrinsic value. After the Q1 surprise and recent pullback, is the market’s caution still warranted?
Most Popular Narrative: 8.2% Undervalued
The most followed narrative for Waters anchors fair value at $401.78 per share, above the last close of $368.98, and leans heavily on high growth expectations.
Further operational leverage from cost synergies, margin improvement initiatives (especially in the microbiology business), and cross-selling opportunities from an expanded product portfolio are expected to drive margin expansion and mid-teens adjusted EPS CAGR for the combined entity through 2030.
Curious what kind of revenue trajectory and margin lift would need to hold for Waters to justify that valuation path? The narrative leans on rapid top line expansion, rising profitability and a rich future earnings multiple that assumes investors keep paying up for this growth story.
Result: Fair Value of $401.78 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Waters investors still face meaningful risks if the BD integration underdelivers on planned synergies or if weaker academic and government demand lingers longer than analysts model.
Find out about the key risks to this Waters narrative.
Another View on Waters Valuation
The first narrative leans on strong growth and an intrinsic value of $471.38 from our DCF model, which suggests Waters is trading at a discount today. Yet the current P/E of 80.6x is well above the fair ratio of 31.8x, the Global Life Sciences average of 38.1x, and the peer average of 28.6x. That leaves investors weighing a generous growth story against a rich earnings multiple that could compress if expectations shift.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals around Waters and its recent Q1 surprise, it helps to move fast and ground your own view in the underlying data, especially as our work highlights at least one risk that worries investors alongside at least one reward that keeps them optimistic, starting with 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Waters?
If Waters has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to uncover fresh stock ideas that fit your style.
- Target resilient income by scanning companies with reliable cash flows and higher yields through the 8 dividend fortresses.
- Hunt for quality at a discount by searching stocks that look attractively priced on fundamentals in the 46 high quality undervalued stocks.
- Prioritise sleep-at-night holdings by filtering for companies with steadier risk profiles using the 83 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com